Clinical Validation of An Optimized Multi-Target Stool DNA (mt-sDNA 2.0) Test, for Colorectal Cancer Screening “BLUE-C” – UROP Spring Symposium 2022

Clinical Validation of An Optimized Multi-Target Stool DNA (mt-sDNA 2.0) Test, for Colorectal Cancer Screening “BLUE-C”

photo of presenter

Sama Khan

Pronouns: she/her/hers

Research Mentor(s): Colin Burnett
Co-Presenter:
Research Mentor School/College/Department: Division of Gastroenterology / Medicine
Presentation Date: April 20
Presentation Type: Poster
Session: Session 1 – 10am – 10:50am
Room: League Ballroom
Authors: Sama Khan, Colin Burnett
Presenter: 30

Abstract

As the third most common cancer that men and women in the US are diagnosed with, colorectal cancer heavily impacts American society and claims lives daily. A study was initiated to explore the ability of the multitarget-stool (mt-s) DNA 2.0 test to detect colorectal neoplasia associated DNA markers and occult hemoglobin in human stool so colorectal cancer or advanced precancerous lesions can be identified. The sub-study collects blood samples in order to evaluate the ability of a blood based test to detect colorectal cancer biomarkers in peripheral blood. The study is actively recruiting those who are ages 40 and over, who have not had a colonoscopy done before, and who are scheduled for a screening colonoscopy. Those who meet eligibility criteria will schedule a study visit which entails survey research and an optional sub-study of a blood collection of 40 mL. The blood study will be used to improve and develop new colorectal cancer screening methods. At this study visit, subjects are also provided with an at-home stool collection kit which they complete and mail to the central laboratory where it will be analyzed for certain biomarkers. Subjects will then undergo their colonoscopy as normal. The colonoscopy and pathology report, if applicable, will be compared to the stool test to assess the accuracy and reliability of the stool test for detecting colorectal cancer when compared to a fecal immunochemical test or a colonoscopy procedure. Currently, there are no findings for the study as it is still ongoing. The ability to detect colorectal cancer early can lead to lower death rates, and we are hopeful that the samples collected will aid in the development of the mt-sDNA 2.0 test and a blood based test for colorectal cancer.

Presentation link

Biomedical Sciences, Interdisciplinary

lsa logoum logo